Twenty plus Years of Data Demonstrating Virus Filtration as an Effective and Robust Step for Large Virus Removal

References

1. 1.↵
   International Conference for Harmonisation, Quality Guideline Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Geneva, 1999.
2. 2.↵
   1. Banton D.,
   2. Vacante D.,
   3. Bulthuis B.,
   4. Goldstein J.,
   5. Wineburg M.,
   6. Schreffler J.

   The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim. PDA J. Pharm. Sci. Technol. 2019, 73 (6), 552–561.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   ASTM International, ASTM E2888-12: Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. ASTM: West Conshohocken, PA, 2012.
4. 4.↵
   ASTM International, ASTM E3042-16: Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment. ASTM: West Conshohocken, PA, 2016.
5. 5.↵
   1. Stuckey J.,
   2. Strauss D.,
   3. Venkiteshwaran A.,
   4. Gao J.,
   5. Luo W.,
   6. Quertinmont M.,
   7. O'Donnell S.,
   8. Chen D.

   A Novel Approach to Achieving Modular Retrovirus Clearance for a Parvovirus Filter. Biotechnol. Prog. 2014, 30 (1), 79–85.

   OpenUrlCrossRef
6. 6.↵
   1. Chen Q.,
   2. Chen D.

   Viral Clearance of Traditional Unit Operations: Virus-Retentive Filtration. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 142–153.

   OpenUrlFREE Full Text
7. 7.↵
   1. Lute S.,
   2. Riordan W.,
   3. Pease L. F.,
   4. Tsai D.-H.,
   5. Levy R.,
   6. Haque M.,
   7. Martin J.,
   8. Moroe I.,
   9. Sato T.,
   10. Morgan M.,
   11. Krishnan M.,
   12. Campbell J.,
   13. Genest P.,
   14. Dolan S.,
   15. Tarrach K.,
   16. Meyer A.,
   17. Zachariah M. R.,
   18. Tarlov M. J.,
   19. Etzel M.,
   20. Brorson K.,
   21. Aranha H.,
   22. Bailey M.,
   23. Bender J.,
   24. Carter J.,
   25. Chen Q.,
   26. Dowd C.,
   27. Jani R.,
   28. Jen D.,
   29. Kidd S.,
   30. Meltzer T.,
   31. Remington K.,
   32. Rice I.,
   33. Romero C.,
   34. Sato T.,
   35. Jornitz M.,
   36. Sekura C. M.,
   37. Sofer G.,
   38. Specht R.,
   39. Wojciechowski P

   , Parenteral Drug Association Virus Filter Task Force. A Consensus Rating Method for Small Virus-Retentive Filters. I. Method Development. PDA J. Pharm. Sci. Technol. 2008, 62 (5), 318–333.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   Parenteral Drug Association Inc. Technical Report No. 41, Revised 2008 (TR41) Virus Filtration. PDA J. Pharm. Sci. Technol. 2008, 62 (S-4).
9. 9.↵
   EMA/CHMP/BWP/187162/2018 Meeting Report: Joint BWP/QWP Workshop with Stakeholders in Relation to Prior Knowledge and Its Use in Regulatory Applications. European Medicines Agency, London, 2018.
10. 10.↵
    1. Strauss D.,
    2. Goldstein J.,
    3. Hongo-Hirasaki T.,
    4. Yokoyama Y.,
    5. Hirotomi N.,
    6. Miyabayashi T.,
    7. Vacante D.

    Characterizing the Impact of Pressure on Virus Filtration Processes and Establishing Design Spaces to Ensure Effective Parvovirus Removal. Biotechnol. Prog. 2017, 33 (5), 1294–1302.

    OpenUrl
11. 11.↵
    1. Miesegaes G.,
    2. Lute S.,
    3. Brorson K.

    Analysis of Viral Clearance Unit Operations for Monoclonal Antibodies. Biotechnol. Bioeng. 2010, 106 (2), 238–246.

    OpenUrlPubMed
12. 12.↵
    1. Mattila J.,
    2. Clark M.,
    3. Liu S.,
    4. Pieracci J.,
    5. Gervais T. R.,
    6. Wilson E.,
    7. Galperina O.,
    8. Li X.,
    9. Roush D.,
    10. Zoeller K.,
    11. Brough H.,
    12. Simpson-Platre C.

    Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration. PDA J. Pharm. Sci. Technol. 2016, 70 (3), 293–299.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Miesegaes G.,
    2. Bailey M.,
    3. Willkommen H.,
    4. Chen Q.,
    5. Roush D.,
    6. Blümel J.,
    7. Brorson K.

    Proceedings of the 2009 Viral Clearance Symposium. Dev. Biol. (Basel, Switz.) 2010, 133, 3–101.

    OpenUrl
14. 14.↵
    U.S. Food and Drug Administration, Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 1997.
15. 15.↵
    European Medicines Agency, EMEA/CHMP/BWP/398498/2005: Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products. EMA: London, 2008.
16. 16.↵
    1. Strauss D. M.,
    2. Cano T.,
    3. Cai N.,
    4. Delucchi H.,
    5. Plancarte M.,
    6. Coleman D.,
    7. Blank G. S.,
    8. Chen Q.,
    9. Yang B.

    Strategies for Developing Design Spaces for Viral Clearance by Anion Exchange Chromatography during Monoclonal Antibody Production. Biotechnol. Prog. 2010, 26 (3), 750–755.

    OpenUrlPubMed
17. 17.↵
    1. Iskra T.,
    2. Sacramo A.,
    3. Gallo C.,
    4. Godavarti R.,
    5. Chen S.,
    6. Lute S.,
    7. Brorson K.

    Development of a Modular Virus Clearance Package for Anion Exchange Chromatography Operated in Weak Partitioning Mode. Biotechnol. Prog. 2015, 31 (3), 750–757.

    OpenUrl
18. 18.↵
    1. LaCasse D.,
    2. Lute S.,
    3. Fiadeiro M.,
    4. Basha J.,
    5. Stork M.,
    6. Brorson K.,
    7. Godavarti R.,
    8. Gallo C.

    Mechanistic Failure Mode Investigation and Resolution of Parvovirus Retentive Filters. Biotechnol. Progress 2016, 32 (4), 959–970.

    OpenUrl